Eli Lilly Fights $278M Drug Royalties Ruling At 9th Circ.
Eli Lilly urged the Ninth Circuit at a hearing on Monday to reverse a finding that it owes an Arizona company $278 million from insulin-brands sales under their royalty agreement, arguing...To view the full article, register now.
Already a subscriber? Click here to view full article